Sign in

XAGE on OTC

Longevity Health Holdings, Inc.

Longevity Health Holdings, Inc. is an American soap company that raised $6 million in 2026 (SEC Form D).1 It is headquartered in Pittsburgh, Pennsylvania.1 Its shares trade on OTC under the symbol XAGE.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with Park Ha Biological Technology Co., Ltd., Meiwu Technology Co Ltd or Orion Bliss Corp., or pick any stock.

  • TickerXAGE on OTC1
  • IndustrySoap, Detergents, Cleang Preparations, Perfumes, Cosmetics1
  • HeadquartersPittsburgh, Pennsylvania1
  • Incorporated inDE2
  • Business address2403 Sidney Street, Suite 300, Pittsburgh, Pa 152032
  • Filer category, Emerging growth company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

57.2%Gross margin4
-371.6%Operating margin4
-361.0%Net margin4
3701.4%Revenue growth, 20254
-$3.3MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue43¢$818.1K
  • Research and development41¢$788.9K
  • Other costs13¢$251.4K
  • Interest1¢$18.2K
  • Income tax2¢$36.3K

Out of $1.9M in revenue.4 The company lost money this year.

Financial statements

Revenue54$1.9M in 2025
0$500.0K$1.0M$1.5M$2.0M2023: $0$020232024: $50.3K$50.3K20242025: $1.9M$1.9M2025+3701%
Gross profit54$1.1M in 2025
0$500.0K$1.0M$1.5M2023: $0$020232024: $44.0K$44.0K20242025: $1.1M$1.1M2025+2390%
Operating income6754-$7.1M in 2025+1421% since 2021
-$8.0M-$6.0M-$4.0M-$2.0M02021: -$467.4K-$467.4K20212022: -$5.5M-$5.5M2022+1078%2023: -$5.9M-$5.9M2023+8%2024: -$5.0M-$5.0M2024−16%2025: -$7.1M-$7.1M2025+42%
Net income6754-$6.9M in 2025+1996% since 2021
-$20.0M-$15.0M-$10.0M-$5.0M02021: -$329.4K-$329.4K20212022: -$9.1M-$9.1M2022+2648%2023: -$15.4M-$15.4M2023+71%2024: -$10.4M-$10.4M2024−33%2025: -$6.9M-$6.9M2025−33%

Every line of the income statement as filed: the last 2 fiscal years, latest first.4

Period ending2025-12-312024-12-31
Gross sales$2.2M$90.8K
Discounts and allowances-$239.5K-$40.5K
Net sales$1.9M$50.3K
Cost of sales$818.1K$6.4K
Gross profit$1.1M$44.0K
Selling and marketing$1.4M$189.3K
Research and development$788.9K$1.1M
General and administrative$5.9M$3.7M
Depreciation and amortization of intangible assets$78.7K$83.5K
Total operating expenses$8.2M$5.0M
Loss from operations-$7.1M-$5.0M
Other income$168.1K$44.8K
Interest expense-$18.2K-$29.5K
Change in fair value of earnout liabilities$149.6K$0
Inventory write-down-$61.0K$0
Amortization of debt discount$0-$19.5K
Loss on forward purchase agreement$0-$5.7M
Loss on lease termination$0-$44.6K
Total other income (expense)$238.6K-$5.7M
Loss from continuing operations before income taxes-$6.9M-$10.7M
Income tax expense (benefit)$36.3K-$97.3K
Loss from continuing operations-$6.9M-$10.7M
Loss from discontinued operations, net of tax$0-$1.2M
Gain on sale of discontinued operations$0$1.4M
Net loss-$6.9M-$10.4M
Net loss from continuing operations - basic-$5-$15
Discontinued operations, net of tax - basic$0$0
Net loss per common share - basic-$4.83-$14.56
Net loss from continuing operations - diluted-$5-$15
Discontinued operations, net of tax - diluted$0$0
Net loss per common share - diluted-$4.83-$14.56
Weighted average of common shares outstanding , Basic1.4M shares712.1K shares
Weighted average of common shares outstanding, Diluted1.4M shares712.1K shares

Compare Longevity Health Holdings, Inc. with another company

Corporate structure

Longevity Health Holdings, Inc. sits at the top of its group. 4 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Longevity Health Holdings, Inc.

  • Longevity Health Holdings, Inc. Pittsburgh, Pennsylvania
    • Carmell Cosmetics Corporation (a wholly-owned subsidiary of the registrant) Subsidiary · Delaware, United States
    • Carmell Regen Med Corporation (a wholly-owned subsidiary of the registrant) Subsidiary · Delaware, United States
    • Elevai Skincare, Inc. (a wholly-owned subsidiary of the registrant) Subsidiary · Delaware, United States

Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Longevity Health Holdings, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$877.4K4 Dec 31, 2025$815.6K4 Dec 31, 2024+7.6%
Accumulated depreciation$775.8K4 Dec 31, 2025$701.7K4 Dec 31, 2024+10.6%
Property and equipment, net$101.6K4 Dec 31, 2025$113.9K4 Dec 31, 2024−10.8%
Operating-lease assets (leased space)$300.2K4 Dec 31, 2025$384.9K4 Dec 31, 2024−22.0%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$706.7K4 Dec 31, 2025$157.1K4 Dec 31, 2024+349.8%

Intangibles and goodwill

ItemLatestA year beforeChange
Accumulated amortization$55.7K4 Dec 31, 2025$51.1K4 Dec 31, 2024+8.9%
Finite-lived intangibles, net$15.1K4 Dec 31, 2025$19.6K4 Dec 31, 2024−23.2%
Patents, net$70.7K4 Dec 31, 2025$70.7K4 Dec 31, 20240%

Inventory

ItemLatestA year beforeChange
Inventory, total$963.0K4 Dec 31, 2025$108.7K4 Dec 31, 2024+785.9%
Raw materials$441.8K4 Dec 31, 2025$86.4K4 Dec 31, 2024+411.4%
Work in process$4.4K4 Dec 31, 2025$19.2K4 Dec 31, 2024−77.2%
Finished goods$516.9K4 Dec 31, 2025$3.1K4 Dec 31, 2024+16648.7%

Properties, in its own words

Our corporate headquarters, research and development, and manufacturing facilities are located in Pittsburgh, Pennsylvania, where we lease approximately 6,432 square feet of space. This lease expires in December 2028. We believe that our existing facilities are adequate to support our operations.

Item 2 of the 10-K filed Mar 31, 2026.11

Leadership

Who has led Longevity Health Holdings, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Rajiv Shukla2021–2023
  2. Randolph W. Hubbell2023
  3. Kendra Bracken-Ferguson2024–2026
  4. J. Ram Ajjarapu2026–now

Chair

  1. Rajiv Shukla2023–now

President

  1. Randolph W. Hubbell2023

Chief financial officer

  1. Patrick A. Sturgeon2021
  2. Bryan J. Cassaday2023–now
2025
Board members and other officers (16)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Appointed as CEO and Chairman of the Board in connection with offering.Janakiram Ajjarapu named Mar 30, 202632
  • DirectorDavid S. Anderson named Apr 30, 202433

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • Carmell Cosmetics Corporation (a wholly-owned subsidiary of the registrant) Delaware3
  • Carmell Regen Med Corporation (a wholly-owned subsidiary of the registrant) Delaware3
  • Elevai Skincare, Inc. (a wholly-owned subsidiary of the registrant) Delaware3

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

  • Carmell CorpAug 1, 2023 to Feb 13, 20252
  • ALPHA HEALTHCARE ACQUISITION CORP IIIFeb 2, 2021 to Jul 20, 20232

Timeline

  1. Sep 8, 20268-K Other events34
  2. Sep 4, 20268-K Entered a material agreement; New debt or obligation; Unregistered sale of shares35
  3. Aug 17, 20268-K Other events36
  4. Aug 14, 20268-K Entered a material agreement; Ended a material agreement; New debt or obligation37
  5. Jun 4, 20268-K Executive or director change38
  6. Apr 8, 2026New chief executive J. Ram Ajjarapu becomes CEO12
  7. Mar 17, 20268-K Entered a material agreement; Unregistered sale of shares; Executive or director change39
  8. Dec 12, 20258-K Ended a material agreement40
  9. Nov 7, 20258-K Entered a material agreement41
  10. Sep 12, 20258-K Listing notice or transfer42
  11. Jul 14, 20258-K Entered a material agreement; Change in control; Other events43
  12. Jun 25, 20258-K Entered a material agreement44
  13. May 28, 20258-K Other events45
  14. Aug 8, 2024New chief executive Kendra Bracken-Ferguson becomes CEO13
  15. Jul 18, 2023New chief executive Randolph W. Hubbell becomes CEO14
  16. Jul 27, 2021New chief executive Rajiv Shukla becomes CEO15

Calendar

When it reported results

  1. May 16, 2025Reported quarterly or annual results46

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

301 filings to the SEC since October 2021: 8 annual reports, 16 quarterly reports, 59 major events, 91 insider forms, 29 large holders, 4 private raises, 94 other. The latest 20:

  1. Sep 8, 2026424B3 EDGAR
  2. Sep 8, 20268-K EDGAR
  3. Sep 8, 2026424B3 EDGAR
  4. Sep 4, 20268-K EDGAR
  5. Aug 17, 2026424B3 EDGAR
  6. Aug 17, 20268-K EDGAR
  7. Aug 14, 2026424B3 EDGAR
  8. Aug 14, 2026424B3 EDGAR
  9. Aug 14, 202610-Q EDGAR
  10. Aug 14, 20268-K EDGAR
  11. Jun 4, 20268-K EDGAR
  12. May 15, 2026424B3 EDGAR
  13. May 15, 202610-Q EDGAR
  14. Apr 8, 2026SCHEDULE 13D EDGAR
  15. Apr 8, 20264 EDGAR
  16. Apr 8, 20263 EDGAR
  17. Mar 31, 2026424B3 EDGAR
  18. Mar 31, 202610-K EDGAR
  19. Mar 30, 2026D EDGAR
  20. Mar 17, 20268-K EDGAR

The 301 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

125 open-market trades by officers, directors and large owners since October 2021: 125 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Mar 16, 2026Ajjarapu J. RamChief Executive OfficerBuy689,656$0.29$200.0KForm 4
Sep 13, 2024Upton Richard ADirectorBuy5,000$0.47$2.4KForm 4
Sep 10, 2024Cassaday Bryan J.Chief Financial OfficerBuy475$0.46$218Form 4
Sep 6, 2024Spenlehauer GillesDirectorBuy1,009$0.51$515Form 4
Sep 6, 2024Gregory KathrynDirectorBuy1,260$0.51$643Form 4
Sep 6, 2024Sturgeon Patrick ADirectorBuy1,261$0.51$643Form 4
Sep 6, 2024Frisch Scott M.DirectorBuy1,009$0.51$515Form 4
Aug 30, 2024Gregory KathrynDirectorBuy109$0.57$62Form 4
Aug 30, 2024Frisch Scott M.DirectorBuy87$0.57$50Form 4
Aug 30, 2024Sturgeon Patrick ADirectorBuy109$0.57$62Form 4
Aug 30, 2024Spenlehauer GillesDirectorBuy87$0.57$50Form 4
Aug 29, 2024Sturgeon Patrick ADirectorBuy652$0.56$365Form 4
Aug 29, 2024Gregory KathrynDirectorBuy652$0.56$365Form 4
Aug 29, 2024Spenlehauer GillesDirectorBuy522$0.56$292Form 4
Aug 29, 2024Frisch Scott M.DirectorBuy522$0.56$292Form 4
Aug 29, 2024Cassaday Bryan J.Chief Financial OfficerBuy1,000$0.57$570Form 4
Aug 29, 2024Anderson David WDirectorBuy652$0.56$365Form 4
Aug 28, 2024Sturgeon Patrick ADirectorBuy970$0.56$543Form 4
Aug 28, 2024Gregory KathrynDirectorBuy1,084$0.56$607Form 4
Aug 28, 2024Spenlehauer GillesDirectorBuy599$0.56$335Form 4

All 125 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$6.0M 2024–2026
Money received by yearMoney received by year, 2024–2026: $6.0M in all. Private raises (Form D) $6.0M.$0$1M$2M$3M2024 · Private raises (Form D): $3.0M20242025 · Private raises (Form D): $2.8M20252026 · Private raises (Form D): $200.0K2026
Figures by year
YearPrivate raises (Form D)Total
2026$200.0K$200.0K
2025$2.8M$2.8M
2024$3.0M$3.0M

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

  1. Mar 16, 2026Raised $200,000 in a private offering of equity32 Form D: 1 investor so far Form D
  2. Jan 16, 2025Raised $975,463 in a private offering of equity59 Form D: $1.1 million offered in all Form D
  3. Jan 2, 2025Raised $1.9 million in a private offering of equity60 Form D: $3.7 million offered in all Form D
  4. Apr 11, 2024Raised $3 million in a private offering of equity33 Form D: 19 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
DRW Securities, LLC14,154$3.7K0.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Longevity Health Holdings, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARLongevity Health Holdings, Inc.1
  • CIK0001842939
  • Employer ID (EIN)86-164573811
  • Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; not a shell company11
  • Incorporated inDelaware11
  • Fiscal year endsDecember 311
  • Industry code (SIC)2840 Soap, Detergents, Cleang Preparations, Perfumes, Cosmetics1
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
  • Business address2403 Sidney Street, Suite 300, Pittsburgh, PA 152031
  • Phone412-894-82481
  • Shares outstanding2,475,321 as of Aug 13, 20269
  • Public float$3.3M as of Jun 30, 202511
  • AuditorAdeptus Partners, LLC, Ocean, New Jersey PCAOB ID 3686; no auditor attestation of internal control over financial reporting11
  • On EDGAR sinceFeb 2, 20211
  • Filings338 in all: 4 (78), 8-K (56), 424B3 (35), 3 (21), CORRESP (20), SC 13G/A (18), 10-Q (16), UPLOAD (13)1
    All 38 form types

    SC 13G (12), 8-K/A (6), 10-K (5), 425 (5), S-1/A (5), S-4/A (5), D (4), EFFECT (4), NT 10-Q (4), 10-K/A (3), DEF 14A (3), S-1 (3), 25-NSE (2), RW (2), S-4 (2), SCHEDULE 13G/A (2), 10-Q/A (1), 424B4 (1), 424B5 (1), 8-A12B (1), ARS (1), CERT (1), DEFA14A (1), DRS (1), NT 10-K (1), POS AM (1), PRE 14A (1), S-3 (1), S-8 (1), SCHEDULE 13D (1)

  • Latest filingsAnnual report (10-K) Mar 31, 2026
    Quarterly report (10-Q) Aug 14, 2026
    Proxy statement (DEF 14A) Feb 10, 2025
    Latest 8-K (8-K) Sep 8, 2026

Risk factors and legal proceedings

The risks Longevity Health Holdings, Inc. names in Item 1A of its 10-K filed Mar 31, 2026: 44 risks under these headings, as written.11

  • Risks Related to Our Business and Operations
  • We have limited experience as a commercial company, and the marketing and sale of our cosmetic products may be unsuccessful.
  • The cosmetics industry is highly competitive, and if we are unable to compete effectively, our results will suffer.
  • Our new product introductions may not be as successful as we anticipate.
  • Acceptance of our formulations or products in the marketplace is uncertain, and failure to achieve market acceptance will prevent or delay our ability to generate revenue.
  • Certain of the products we process are derived from human tissue and therefore have the potential for disease transmission.
  • If we cannot successfully address quality issues that may arise with our products, our brand reputation could suffer, and our business, financial condition, and results of operations could be adversely impacted.
  • Our success depends largely upon consumer satisfaction with the aesthetic results of our products.
  • We may fail to retain or recruit necessary personnel, and we may be unable to secure the services of consultants.
  • We rely on third parties to supply certain raw materials and packaging components and to manufacture and package certain of our products, and if our third-party vendors do not timely supply these products or perform these services, it may delay or impair our ability to develop, manufacture, market, and deliver our products.
  • To be commercially successful, we must educate physicians, where appropriate, on how and when our products are proper alternatives to existing treatments and that our products should be used in their procedures.
  • If we do not manage inventory in an effective and efficient manner, it could adversely affect our results of operations.
The other 33 risks
  • We will need substantial additional funding. If we are unable to raise capital when needed, we could be forced to delay, reduce, or eliminate our product development programs or commercialization efforts.
  • We may engage in strategic transactions that could impact our liquidity, increase our expenses, and present significant distractions to our management.
  • Our financial condition, results of operations, and cash flow may be adversely affected by changing economic conditions, including interest rates and inflation.
  • Risks Related to Legal and Regulatory Matters
  • New laws, regulations, enforcement trends, or changes in existing regulations governing the introduction, marketing, and sale of our products to consumers could harm our business.
  • Government regulations and private party actions relating to the marketing and advertising of our products and services may restrict, inhibit, or delay our ability to sell our products and harm our business, financial condition, and results of operations.
  • Our products may cause or contribute to undesirable side effects that we are required to report to the FDA, and if we fail to do so, we would be subject to sanctions that could harm our reputation, business, financial condition, and results of operations.
  • Product liability lawsuits could divert our resources, result in substantial liabilities, and reduce the commercial potential of our products.
  • We may be subject to damages resulting from claims that we or our employees have wrongfully used or disclosed alleged trade secrets of our competitors or are in breach of non-competition or non-solicitation agreements with our competitors.
  • Business interruptions could adversely affect future operations and financial conditions and may increase our costs and expenses.
  • Our employees or others acting on our behalf may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could cause significant liability for us and harm our reputation.
  • Risks Related to Our Intellectual Property
  • We may not be able to protect our proprietary technology, which could harm our ability to operate profitably.
  • We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights, as well as costs associated with lawsuits.
  • If we infringe the rights of others, we could be prevented from selling products or forced to pay damages.
  • We cannot be certain we will be able to obtain and maintain patent protection to protect our products and technology.
  • We may infringe the intellectual property rights of others, which may prevent or delay our product development efforts and stop us from commercializing or increase the costs of commercializing our cosmetic products.
  • If we fail to protect or enforce our intellectual property or confidential proprietary information relating to cosmetic products, we may not be able to compete effectively, which may negatively affect our business as well as limit our partnership or acquisition appeal.
  • If we are not able to protect and control our unpatented trade secrets, know-how, and other proprietary technology, we may suffer competitive harm.
  • If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our target markets, and our business may be adversely affected.
  • Risks Related to Our Financial Condition
  • Our future success is dependent, in part, on the performance and continued service of our officers and directors.
  • Management has concluded that there is substantial doubt about our ability to continue as a going concern.
  • We may become involved in litigation that may materially adversely affect us.
  • We have a history of net losses, and we may not be able to achieve or maintain profitability in the future.
  • An economic downturn may harm our business and the results of our operations.
  • Future increases in interest rates may increase our borrowing costs and may also affect our ability to obtain working capital through borrowings such as bank credit lines and public or private sales of debt securities, which may result in lower liquidity, reduced working capital, and other adverse impacts on our business.
  • Significant disruptions of information technology systems, computer system failures, or breaches of information security could adversely affect our business.
  • We will need to grow the size of our organization in the future, and we may experience difficulties in managing this growth.
  • Risks Related to Our Common Stock
  • We expect the price of our Common Stock may be volatile and may fluctuate substantially.
  • Future resales of Common Stock may cause the market price of our securities to drop significantly, even if our business is doing well.
  • Our largest stockholder will have the ability to influence the outcome of director elections and other matters requiring stockholder approval.
  • We are required to register the issuance of the shares underlying the warrants issued in the IPO. We may incur substantial costs in connection with such registration statement, and the issuance of such shares may result in dilution to holders of our Common Stock, and the issuance of any such shares upon a cashless exercise of the warrants would not result in the receipt by us of any cash proceeds thereof.
  • We are an “emerging growth company,” and the reduced disclosure requirements applicable to emerging growth companies may make our Common Stock less attractive to investors.
  • We do not anticipate paying any cash dividends on our Common Stock in the foreseeable future; capital appreciation, if any, will be your sole source of gain as a holder of our Common Stock.
  • Provisions in our amended and restated certificate of incorporation and Delaware law may inhibit a takeover of us, which could limit the price investors might be willing to pay in the future for our Common Stock and could entrench management.

Legal proceedings

The information under the headings “January 2022 Convertible Notes” in Note 11 - Contingencies in the notes to the accompanying consolidated financial statements is incorporated herein by reference.

The opening of Item 3, Legal Proceedings.11

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
    SEC EDGAROther events
  35. 35
  36. 36
    SEC EDGAROther events
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
    SEC EDGAROther events
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60